Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, MD, Radhakrishnan Ramchandren, MD, Michael Maris, MD, Alexander M. Lesokhin, MD, Gottfried R. von Keudell, MD PhD, Bruce D. Cheson, MD, Jeff Zonder, MD, Erlene K. Seymour, MD, Tina Catalano, MSc, Gloria H. Y. Lin, PhD, Bob Uger, PhD, Penka S. Petrova, PhD, Kathleen Roberge, ANP, MSc, Yaping Shou, MDPhD, Swami P. Iyer, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136607

Published: 2020

Journal Articles

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

John E. Godwin, MD, Cesar O. Freytes, MD, Michael Maris, MD, Don A. Stevens, MD, Daanish Hoda, MD, Bassam Mattar, MD, Juan C. Varela, MDPhD, Mohamad Cherry, MDMS, James Essell, MD, Jay Courtright, MD, Suzanne R. Fanning, DO, Habte A. Yimer, MD, Nikolaus S. Trede, MD PhD, Marina Youssef, PharmD, James Lymp, PhD, Carlos Bachier, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-136640

Published: 2020

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-136198

Published: 2020

Journal Articles

Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia

Eunice S. Wang, MD, Olga Frankfurt, MD, Keith William Orford, MD PhD, Mark Bennett, PhD, Ian W. Flinn, MD PhD, Michael Maris, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 2566.

https://doi.org/10.1182/blood.V126.23.2566.2566

Published: 2015

Journal Articles

Combination Trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in Patients with Lymphoma or Chronic Lymphocytic Leukemia

Ian W. Flinn, MD PhD, Mohamad Cherry, MD, Michael Maris, MD, Jeffrey V. Matous, MD, Jesus G. Berdeja, MD, Manish R. Patel, MD

Blood (2015) 126 (23): 3928.

https://doi.org/10.1182/blood.V126.23.3928.3928

Published: 2015

Journal Articles

A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Jesus G. Berdeja, MD, Rami S. Komrokji, MD, James Essell, MD, Roger M. Lyons, MD, Michael Maris, MD, Amy E. DeZern, MD MHS, Mikkael A. Sekeres, MD MS, Gail J Roboz, MD

Blood (2015) 126 (23): 911.

https://doi.org/10.1182/blood.V126.23.911.911

Published: 2015

Journal Articles

BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

Jeremy S. Abramson, MD, Kristie A. Blum, MD, Ian W. Flinn, MD PhD, Martin Gutierrez, MD, Andre Goy, MD, Michael Maris, MD, Michael Cooper, MD, Michael O'Meara, MS, Darrell Borger, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Supko Jeffrey, PhD, Anas Younes, MD

Blood (2015) 126 (23): 1491.

https://doi.org/10.1182/blood.V126.23.1491.1491

Published: 2015

Journal Articles

A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Larry D. Cripe, Michael Maris, MD, Maureen Cooper, MD, Shaker R. Dakhil, MD, Richard M Stone, MD, Francesco Turturro, MD, Tianling Chen, MD, MSc, Kristi Mahadocon, Judith Fox, Craig Berman, Glenn C Michelson, MD, Robert K Stuart

Blood (2009) 114 (22): 1037.

https://doi.org/10.1182/blood.V114.22.1037.1037

Published: 2009

Journal Articles

Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia.

Ron Ram, MD, Rainer F. Storb, MD, David G. Maloney, MD, Brenda M. Sandmaier, MD, Michael Maris, MD, Judith Shizuru, MD, PhD, Thomas Chauncey, MD, PhD, Amelia A. Langston, MD, George E. Georges, MD

Blood (2009) 114 (22): 1210.

https://doi.org/10.1182/blood.V114.22.1210.1210

Published: 2009

Journal Articles

Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization.

Paul Shaughnessy, MD, Miguel Islas-Ohlmayer, MD, Julie Murphy, Maureen Hougham, RN, Jill MacPherson, FNP, Kurt Winkler, PharmD, Matthew Silva, PharmD, Michael Steinberg, PharmD, Jeffrey Matous, MD, Sheryl Selvey, PharmD, Michael Maris, MD, Peter A. McSweeney, MD

Blood (2009) 114 (22): 2277.

https://doi.org/10.1182/blood.V114.22.2277.2277

Published: 2009

Journal Articles

Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients.

Jeffrey E Lancet, MD, Gail J. Roboz, MD, Larry D. Cripe, Michael Maris, MD, Alan F List, MD, Judith Fox, Glenn C Michelson, MD, Judith Karp

Blood (2009) 114 (22): 635.

https://doi.org/10.1182/blood.V114.22.635.635

Published: 2009

Journal Articles

A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial.

Brenda M. Sandmaier, MD, Michael Maris, MD, Barry Storer, PhD, Lars Vindelov, MD, Amelia Langston, MD, James C. Wade, MD, MPH, Wolfgang A. Bethge, MD, Michael Pulsipher, MD, Thoralf Lange, MD, Thomas Chauncey, MD, Finn Petersen, MD, Kai Hübel, MD, Ann Woolfrey, MD, Mary E.D. Flowers, MD, David G. Maloney, MD, PhD, Rainer F. Storb, MD

Blood (2009) 114 (22): 348.

https://doi.org/10.1182/blood.V114.22.348.348

Published: 2009

Journal Articles

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Sibling or Unrelated Donor Hematopoietic Cell Transplants in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Tara Gregory, MD, Mark W. Brunvand, MD, Peter A. McSweeney, MD, Scott I. Bearman, MD, Michael Maris, MD, Jeffrey Matous, MD

Blood (2009) 114 (22): 3354.

https://doi.org/10.1182/blood.V114.22.3354.3354

Published: 2009

Journal Articles

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Mohamed L. Sorror, MD, MS, Barry Storer, PhD, Brenda M. Sandmaier, MD, Michael Maris, MD, Thomas Chauncey, MD, Richard T. Maziarz, MD, Michael Pulsipher, MD, Judith Shizuru, MD, PhD, Dietger Niederwieser, MD, Edward Agura, MD, James C. Wade, MD, MPH, Amelia A Langston, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD

Blood (2008) 112 (11): 2147.

https://doi.org/10.1182/blood.V112.11.2147.2147

Published: 2008

Journal Articles

Phase 2 Study of Voreloxin (Formerly Known as SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses (The REVEAL-1 Study).

Michael Maris, MD, Larry D. Cripe, MD, Robert K Stuart, MD, Farhad Ravandi, MBBS, Glenn C Michelson, MD, Rachel E. Hawtin, PhD, Lyra E Ericson, Craig J. Berman, MD

Blood (2008) 112 (11): 1951.

https://doi.org/10.1182/blood.V112.11.1951.1951

Published: 2008

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Blood (2008) 112 (11): 2162.

https://doi.org/10.1182/blood.V112.11.2162.2162

Published: 2008

Journal Articles

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

Blood (2008) 112 (11): 149.

https://doi.org/10.1182/blood.V112.11.149.149

Published: 2008

Journal Articles

Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.

Azra Raza, MD, Joseph G. Jurcic, MD, Gail J. Roboz, MD, Michael Maris, MD, Joseph Stephenson, MD, Brent L. Wood, MD, Bhaskar Rege, PhD, Laurie E. Grove, PA-C, Jonathan G. Drachman, MD, Eric L. Sievers, MD

Blood (2007) 110 (11): 159.

https://doi.org/10.1182/blood.V110.11.159.159

Published: 2007

Journal Articles

A Large Cohort Analysis of CMV Viral Load and Ganciclovir-Related Neutropenia in Nonmyeloablative (NM-HCT) and Myeloablative (M-HCT) Allogeneic Hematopoietic Cell Transplant Recipients.

Hirohisa Nakamae, MD, Katharine A. Kirby, MS, Brenda M. Sandmaier, MD, Lalita Norasetthada, MD, David Maloney, MD, Michael Maris, MD, Chris Davis, MD, Lawrence Corey, MD, Rainer Storb, MD, Michael Boeckh, MD

Blood (2007) 110 (11): 2975.

https://doi.org/10.1182/blood.V110.11.2975.2975

Published: 2007

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Andrew R. Rezvani, MD, L. Norasetthada, MD, T. Gooley, PhD, Mohamed Sorror, MD, Stephen J. Forman, MD, Edward Agura, MD, T. Chauncey, MD, PhD, Richard T. Maziarz, MD, Michael Maris, MD, J. Shizuru, MD, PhD, B. Bruno, MD, James C. Wade, MD, T. Lange, MD, Andrew Yeager, MD, Brenda M. Sandmaier, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD

Blood (2007) 110 (11): 3037.

https://doi.org/10.1182/blood.V110.11.3037.3037

Published: 2007

NARROW

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia

Combination Trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in Patients with Lymphoma or Chronic Lymphocytic Leukemia

A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)

BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia.

Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization.

Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients.

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Sibling or Unrelated Donor Hematopoietic Cell Transplants in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Phase 2 Study of Voreloxin (Formerly Known as SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses (The REVEAL-1 Study).

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.

A Large Cohort Analysis of CMV Viral Load and Ganciclovir-Related Neutropenia in Nonmyeloablative (NM-HCT) and Myeloablative (M-HCT) Allogeneic Hematopoietic Cell Transplant Recipients.

Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only